Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomised controlled trial.
OBJECTIVE
To see whether there is a difference in outcome between patients treated with oral and intravenous antibiotics for lower respiratory tract infection.


METHODS
Open controlled trial in patients admitted consecutively and randomised to treatment with either oral co-amoxiclav, intravenous followed by oral co-amoxiclav, or intravenous followed by oral cephalosporins.


METHODS
Large general hospital in Dublin.


METHODS
541 patients admitted for lower respiratory tract infection during one year. Patients represented 87% of admissions with the diagnosis and excluded those who were immunocompromised and patients with severe life threatening infection.


METHODS
Cure, partial cure, extended antibiotic treatment, change of antibiotic, death, and cost and duration of hospital stay.


RESULTS
There were no significant differences between the groups in clinical outcome or mortality (6%). However, patients randomised to oral co-amoxiclav had a significantly shorter hospital stay than the two groups given intravenous antibiotic (median 6 v 7 and 9 days respectively). In addition, oral antibiotics were cheaper, easier to administer, and if used routinely in the 800 or so patients admitted annually would lead to savings of around 176,000 pounds a year.


CONCLUSIONS
Oral antibiotics in community acquired lower respiratory tract infection are at least as efficacious as intraveous therapy. Their use reduces labour and equipment costs and may lead to earlier discharge from hospital.
Chan
R
R
Department of Therapeutics, Trinity Centre for Health Science, St James's Hospital, Dublin.
Hemeryck
L
L
O'Regan
M
M
Clancy
L
L
Feely
J
J
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000008:administration & dosage / Q000191:economics; D019980:Amoxicillin-Potassium Clavulanate Combination; D002969:Clavulanic Acids / Q000008:administration & dosage / Q000191:economics; D017714:Community-Acquired Infections / Q000188:drug therapy / Q000191:economics; D016527:Drug Costs; D004359:Drug Therapy, Combination / Q000008:administration & dosage* / Q000191:economics; D005260:Female; D017721:Hospital Costs; D006769:Hospitals, General; D006801:Humans; D007262:Infusions, Intravenous; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000191:economics; D013183:Sputum / Q000382:microbiology; D016896:Treatment Outcome
D002969:Clavulanic Acids; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin